Form 4: MAIA Biotechnology Director Stan Smith Granted Stock Options

MAIA Biotechnology, Inc. Director Stan Smith was granted 24,747 stock options with an exercise price of $1.8 per share, vesting immediately.

Summary

• Stan Smith, a Director of MAIA Biotechnology, Inc. (MAIA), was granted 24,747 stock options.
• The stock options were granted on June 30, 2025, under the company's 2021 Equity Incentive Plan.
• Each option allows the holder to purchase one share of common stock at an exercise price of $1.8.
• The options vest 100% on the grant date, June 30, 2025, and are exercisable immediately from that date.
• The expiration date for these stock options is June 30, 2035.
• The securities are beneficially owned indirectly by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (stock option grant) which is generally neutral but can be seen as slightly positive due to increased alignment of a director's interests with shareholders.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The options vest immediately, providing the director with immediate equity exposure and potential upside.

Future Outlook

The document does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on an insider's transaction.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries, particularly in biotechnology where equity incentives are a standard component of executive and director compensation to align interests with long-term company growth.

Comparison to Industry Standards

• The grant of stock options to directors is a common practice in the biotechnology industry, similar to companies like Moderna or BioNTech, to incentivize long-term commitment and performance.
• The immediate vesting of options on the grant date is less common than phased vesting schedules but can be seen in some compensation structures, particularly for non-employee directors, to provide immediate equity alignment.
• The exercise price of $1.8 per share is specific to MAIA's stock valuation at the time of grant and would need to be compared against the company's stock price performance and peer group option grants for a comprehensive assessment.

Corporate Governance

Related Party Transactions

• The securities are beneficially owned indirectly by Mr. Smith through The Stan V. Smith Trust Dated 1993, indicating a related party transaction where the beneficial ownership is held through a trust associated with the director.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor dilution if exercised, but also aligns the director's interests with shareholder value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The granted stock options are exercisable as of June 30, 2025, and can be exercised by the reporting person at any time until their expiration on June 30, 2035.

Key Dates

Keywords

MAIA Biotechnology, MAIA, Stock Options, SEC Form 4, Insider Transaction, Equity Incentive Plan, Director Compensation, Stan Smith